

MEDAREX INC  
Form 8-K  
April 06, 2006

**As filed with the Securities and Exchange Commission on April 5, 2006.**

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549



**FORM 8-K**



**CURRENT REPORT**



Edgar Filing: MEDAREX INC - Form 8-K

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**April 5, 2006 (April 5, 2006)**

---

**MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**  
(State of other jurisdiction  
of incorporation)

**0-19312**  
(Commission File Number)

**22-2822175**  
(IRS Employer  
Identification No.)



707 State Road, Princeton, N.J. 08540-1437

Edgar Filing: MEDAREX INC - Form 8-K

(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: (609) 430-2880**

**Not Applicable**

Edgar Filing: MEDAREX INC - Form 8-K

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**MEDAREX, INC.**

**TABLE OF CONTENTS**

**FOR**

**CURRENT REPORT ON FORM 8-K**

Item 8.01

Other Events

Item 9.01

Financial Statements and Exhibits.

Signature

**Item 8.01. Other Events.**

On April 5, 2006, Medarex, Inc. released certain information relating to certain of its clinical trials of ipilimumab (also known as MDX-010). A copy of the such information is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit  
Number**

99.1 Medarex, Inc. Information relating to certain clinical trials of ipilimumab (also known as MDX-010) Press Release dated April 5, 2006.



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAREX, INC.  
Registrant

Date: April 5, 2006

By: */s/ W. Bradford Middlekauff*  
*W. Bradford Middlekauff*  
*Senior Vice Presiden, General Counsel and Secretary*

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Page Number</b>
99.1	Medarex, Inc. Information relating to certain clinical trials of ipilimumab (also known as MDX-010) dated April 5, 2006.	